The Experts below are selected from a list of 16752 Experts worldwide ranked by ideXlab platform

Arnold A. Lazarus - One of the best experts on this subject based on the ideXlab platform.

  • Multimodal Therapy
    Handbook of Psychotherapy Integration, 2019
    Co-Authors: Clifford N. Lazarus, Arnold A. Lazarus
    Abstract:

    Arnold Lazarus pioneered cognitive-behavior Therapy but soon realized that it contained significant treatment omissions. He thus created Multimodal Therapy (MMT), a comprehensive, biopsychosocial approach to psychological assessment and technically eclectic psychoTherapy. Unlike traditional cognitive-behavior Therapy, in addition to focusing on behavior, cognition, and affect, MMT also thoroughly assesses imagery, sensations, interpersonal relationships, and biological factors, which results in a comprehensive diagnostic and treatment planning framework. This chapter features the foundations of MMT, its applicability and structure, its Therapy relationship, and its key methods. The chapter concludes with case example, a review of outcome research, and several future directions.

  • Multimodal Therapy
    Handbook of Psychotherapy Integration, 2005
    Co-Authors: Arnold A. Lazarus
    Abstract:

    Chapter 5 discusses Multimodal Therapy, and how the Multimodal approach provides a framework that facilitates systematic treatment selection in a broad-based, comprehensive, and yet highly focused manner. It covers how it respects science and data-driven findings, and it endeavors to use empirically supported methods when possible. Nevertheless, it recognizes that many issues still fall into the grey area in which artistry and subjective judgment are necessary and tries to fill the void by offering methods that have strong clinical support.

  • The Case of "Ben": A Flexible, Holistic Application of Multimodal Therapy
    Pragmatic Case Studies in Psychotherapy, 2004
    Co-Authors: Arnold A. Lazarus
    Abstract:

    "Ben," a white, male executive who was 50 years old at the beginning of Therapy, presented with anxiety, depressive mood, anger, and relationship and career problems. The case, involving Therapy in a private practice setting, illustrates some of the diverse individual client needs, life complexities, and accompanying twists and turns that can emerge in treatment. While grounded in a cognitive-behavioral framework, the "Multimodal Therapy" model employed in Ben's case is designed to be responsive to such challenges by drawing procedures from other traditions, when necessary, within the framework of a "technical eclecticism." In addition, the case illustrates attempts within the Multimodal model to balance science versus artistry, and planned structure vs. creativity and flexibility.

Trinity J Bivalacqua - One of the best experts on this subject based on the ideXlab platform.

  • Multimodal Therapy in the treatment of prostate sarcoma the johns hopkins experience
    Clinical Genitourinary Cancer, 2015
    Co-Authors: Mark W Ball, Debasish Sundi, Adam C Reese, Christian F Meyer, Stephanie A Terezakis, Jonathan E Efron, Mark P Schoenberg, Jonathan I Epstein, Nita Ahuja, Trinity J Bivalacqua
    Abstract:

    Background The objective of this study was to evaluate the use of neoadjuvant chemoradiation in patients with prostate sarcoma treated at our institution and report oncological outcomes. Materials and methods The records of patients with intermediate- or high-grade prostate sarcoma treated with curative intent at our institution from 1993 to 2013 were reviewed. Patient demographic information, tumor characteristics, and treatment modalities used were assessed. Overall survival (OS), cancer-specific survival (CSS), and recurrence-free survival (RFS) were calculated. Results Eight patients met inclusion criteria. The mean age at presentation was 64 years, and urinary obstruction was the most common presenting symptom. All patients underwent surgical resection and neoadjuvant radiation and 6 had concurrent chemoTherapy. Four patients received intraoperative radiation. With a median follow-up of 36 months, there were no local recurrences, 6 metastases, 4 deaths from disease, and no deaths from other causes. The median OS and CSS was 67.8 months, with actuarial OS and CSS rates of 100% at 1 year, 75% at 2 years, 62.5% at 3 years, and 62.5% at 5 years. Median RFS was 14.2 months, with actuarial RFS rate of 75% at 1 year, 37.5% at 2 years, and 25% at 3 years. Conclusion Prostate sarcomas are rarely cured using surgical resection alone. Our cohort treated with a Multimodality approach had favorable CSS and RFS compared with historic and contemporary series of surgery alone and no local recurrences. Most patients developed metastatic recurrence, highlighting the aggressive nature of this disease.

Daniel J. Sargent - One of the best experts on this subject based on the ideXlab platform.

  • Refining Multimodal Therapy for Rectal Cancer
    The New England journal of medicine, 2001
    Co-Authors: Heidi D Nelson, Daniel J. Sargent
    Abstract:

    For a short time, the treatment of rectal cancer seemed clear and definitive. The 1990 National Institutes of Health consensus statement concluded, “Combined postoperative chemoTherapy and radiation Therapy improves local control and survival in stage II and III patients and is recommended.”1 At the time, the generally accepted treatment was conventional bowel resection followed by adjuvant radiation Therapy (at a dose of 45 to 55 Gy) and chemoTherapy if pathological findings confirmed the presence of transmural invasion or positive lymph nodes. Although the consensus statement introduced Multimodal Therapy as the standard treatment, results from subsequent randomized, controlled trials challenged that . . .

Joseph Rubin - One of the best experts on this subject based on the ideXlab platform.

  • survival in response to Multimodal Therapy in anaplastic thyroid cancer
    The Journal of Clinical Endocrinology and Metabolism, 2017
    Co-Authors: Naiyarat Prasongsook, Ashish V Chintakuntlawar, Robert L Foote, Jan L Kasperbauer, Aditi Kumar, Julian R Molina, Yolanda I Garces, Daniel J, Michelle Neben A Wittich, Joseph Rubin
    Abstract:

    Context Historical outcomes in anaplastic thyroid cancer (ATC) have been dismal. Objective To determine whether an initial intensive Multimodal Therapy (MMT) is associated with improved ATC survival. Design MMT was offered to all patients with newly diagnosed ATC treated at the Mayo Clinic from 2003 through 2015; MMT vs care with palliative intent (PI) was individualized considering clinical status and patient preferences. Outcomes were retrospectively analyzed by American Joint Committee on Cancer stage and treatments compared with patient cohort data from 1949 through 1999. Patients Forty-eight patients (60% male; median age, 62 years); 18 treated with PI, 30 with MMT. Main Outcome Measure Overall survival (OS) and progression-free survival determined by Kaplan-Meier method. Results Median OS and 1-year survival for the later cohort were 9 months [95% confidence interval (CI), 4 to 22 months] and 42% (95% CI, 28% to 56%) vs 3 months and 10% for the earlier cohort. Median OS was 21 months compared with 3.9 months in the pooled MMT vs PI groups for the later cohort [hazard ratio (HR), 0.32; P = 0.0006]. Among only patients in the later cohort who had stage IVB disease, median OS was 22.4 vs 4 months (HR, 0.12; 95% CI, 0.03 to 0.44; P = 0.0001), with 68% vs 0% alive at 1 year (MMT vs PI). Among patients with stage IVC cancer, OS did not differ by Therapy. Conclusion MMT appears to convey longer survival in ATC among patients with stage IVA/B disease.

Ashish V Chintakuntlawar - One of the best experts on this subject based on the ideXlab platform.

  • survival in response to Multimodal Therapy in anaplastic thyroid cancer
    The Journal of Clinical Endocrinology and Metabolism, 2017
    Co-Authors: Naiyarat Prasongsook, Ashish V Chintakuntlawar, Robert L Foote, Jan L Kasperbauer, Aditi Kumar, Julian R Molina, Yolanda I Garces, Daniel J, Michelle Neben A Wittich, Joseph Rubin
    Abstract:

    Context Historical outcomes in anaplastic thyroid cancer (ATC) have been dismal. Objective To determine whether an initial intensive Multimodal Therapy (MMT) is associated with improved ATC survival. Design MMT was offered to all patients with newly diagnosed ATC treated at the Mayo Clinic from 2003 through 2015; MMT vs care with palliative intent (PI) was individualized considering clinical status and patient preferences. Outcomes were retrospectively analyzed by American Joint Committee on Cancer stage and treatments compared with patient cohort data from 1949 through 1999. Patients Forty-eight patients (60% male; median age, 62 years); 18 treated with PI, 30 with MMT. Main Outcome Measure Overall survival (OS) and progression-free survival determined by Kaplan-Meier method. Results Median OS and 1-year survival for the later cohort were 9 months [95% confidence interval (CI), 4 to 22 months] and 42% (95% CI, 28% to 56%) vs 3 months and 10% for the earlier cohort. Median OS was 21 months compared with 3.9 months in the pooled MMT vs PI groups for the later cohort [hazard ratio (HR), 0.32; P = 0.0006]. Among only patients in the later cohort who had stage IVB disease, median OS was 22.4 vs 4 months (HR, 0.12; 95% CI, 0.03 to 0.44; P = 0.0001), with 68% vs 0% alive at 1 year (MMT vs PI). Among patients with stage IVC cancer, OS did not differ by Therapy. Conclusion MMT appears to convey longer survival in ATC among patients with stage IVA/B disease.

  • expression of pd 1 and pd l1 in anaplastic thyroid cancer patients treated with Multimodal Therapy results from a retrospective study
    The Journal of Clinical Endocrinology and Metabolism, 2017
    Co-Authors: Ashish V Chintakuntlawar, Kandelaria M Rumilla, Carin Y Smith, Sarah M Jenkins, Robert L Foote, Jan L Kasperbauer, John C Morris, Mabel Ryder, Samer Alsidawi, Crystal Hilger
    Abstract:

    Context Anaplastic thyroid cancer (ATC) is rare and a highly fatal malignancy. The role of programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1) as prognostic and/or predictive markers in ATC is unknown. Objective Multimodal Therapy offers the best chance at tumor control. The objective of this study was to detect potential associations of PD-1/PD-L1 axis variables with outcome data in ATC. Design Retrospective study of a uniformly treated cohort. Setting Single institution retrospective cohort study. Patients or Other Participants Sixteen patients who received intensity-modulated radiation Therapy (15 had preceding surgery) were studied. Main Outcome Measure Patients treated with Multimodal Therapy were followed and assessed for overall survival (OS) and progression-free survival (PFS). Results All samples demonstrated PD-1 expression in inflammatory cells whereas tumor cells were primarily negative. PD-L1 was expressed on ATC tumor cells in most samples and showed mainly membranous staining. High PD-1 expression (>40% staining) in inflammatory cells was associated with worse overall survival (OS; hazard ratio, 3.36; 95% confidence interval, 1.00 to 12.96; P 33% staining) trended toward worse PFS and OS. Conclusion PD-1/PD-L1 pathway proteins are highly expressed in ATC tumor samples and appear to represent predictive markers of PFS and OS in Multimodality-treated ATC patients.